• Corpus ID: 30281263

Pharmacokinetics of carboplatin after i.v. administration.

  title={Pharmacokinetics of carboplatin after i.v. administration.},
  author={F. Elferink and Wim J.F. van der Vijgh and Ina Klein and Jan Baptist Vermorken and Helen E. Gall and Herbert Michael Pinedo},
  journal={Cancer treatment reports},
  volume={71 12},
Pharmacokinetics of the cisplatin analog carboplatin were studied in ovarian cancer patients who received short-term iv infusions of 290-370 mg/m2. Platinum (Pt) was determined by atomic absorption spectrometry in plasma ultrafiltrate up to 24 hours and in plasma and urine up to 5 days following infusion. Carboplatin was determined in plasma ultrafiltrate and in urine by high-performance liquid chromatography with electrochemical detection. The final half-life of total Pt in plasma was 5.8… 
Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.
Plasma ultrafiltrated Pt and Carboplatin decreased to undetectable levels within 48 h, but total Pt was detectable until 96 h after the last carboplatin dose, so bone marrow reinfusion can be safely performed at 48 h after repeated dosing ofcarboplatin on three consecutive days.
Clinical pharmacokinetics of carboplatin in children
In children with normal renal function, a limited interpatient variability of the peak plasma concentration and the area under the concentration-time curve (AUC) is found and a linear correlation between the dose and both Cmax and AUC is observed.
Pharmacokinetic evaluation of zeniplatin in humans
Findings suggest that zeniplatin has a pharmacokinetic profile similar to that of carboplatin, and could be recovered in the urine within 24 h.
A phase I and pharmacokinetics study of prolonged ambulatory-infusion carboplatin
Non-hematological toxicities were predominantly gastrointestinal, with 3 of 18 patients experiencing grade 3 emesis, and neither neutropenia nor thrombocytopenia could be related to steady-state UFPT or the UFPt area under the concentration-time curve (AUC).
Involving service users in health and social care research
  • I. Karlberg
  • Medicine, Chemistry
    International Journal of Integrated Care
  • 2006
Pharmacokinetics of the cisplatin analogue carboplatin were studied in patients with disseminated ovarian and testicular cancer as part of an ablative combination regimen followed by autologous bone marrow transplantation.
Pharmacokinetics of high-dose carboplatin in children undergoing high-dose chemotherapy and autologous stem cell transplantation with BSA-based dosing
Positive correlations between the renal functions and the AUCs were mild to moderate, but they were stronger in nephrectomized patients, and optimal high-dose carboplatin dosing method and optimal target A UCs for the different tumors need further analysis.
Renal handling of carboplatin
It is concluded that the renal elimination of carboplatin takes place by glomerular filtration followed by tubular reabsorption in ovarian cancer patients treated with a combination of Carboplatin and cyclophosphamide.
Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients
The model is a useful guide in the calculation of the carboplatin dose to be given in combination with cyclophosphamide, and it enables a more precise prediction of thecarboplatin exposure than does the conventional calculation, which is based on milligrams of drug per square meter of body surface.
Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
It can be concluded that the hematological toxicity and the pharmacokinetics of lobaplatin are strongly affected by renal function.